CoChat

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Financial implications of protocol-based hypertension treatment: an insight into medication costs in public and private health sectors in India

Open access

Abstract

Hypertension is a major public health challenge in low- and middle-income countries (LMICs) and calls for large-scale effective hypertension control programs. Adoption of drug and dose-specific treatment protocols recommended by the World Health Organization-HEARTS Initiative is key for hypertension control programs in LMICs. We estimated the annual medication cost per patient using three such protocols (protocol-1 and protocol-2 with Amlodipine, Telmisartan, using add-on doses and different drug orders, adding Chlorthalidone; protocol-3 with a single-pill combination (SPC) of Amlodipine/Telmisartan with dose up-titration, and addition of Chlorthalidone, if required) in India. The medication cost was simulated with different hypertension control assumptions for each protocol and calculated based on prices in the public and private sectors in India. The estimated annual medication cost per patient for protocol-1 and protocol-2 was $33.88–58.44 and $51.57–68.83 for protocol-3 in the private sector. The medication cost was lower in the generic stores ($5.78–9.57 for protocol-1 and protocol-2, and $7.35–9.89 for protocol-3). The medication cost for patients was the lowest ($2.05–3.89 for protocol-1 and protocol-2, and $2.94–3.98 for protocol-3) in the public sector. At less than $4 per patient per annum, scaling up a hypertension control program with specific treatment protocols is a potentially cost-effective public health intervention. Expanding low-cost generic retail networks would extend affordability in the private sector. The cost of treatment with SPC is comparable with non-SPC protocols and can be adopted in a public health program considering the advantage of simplified logistics, reduced pill burden, improved treatment adherence, and blood pressure control.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41371-022-00766-x

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 17 references

Research works printed but not linked: 1

  1. Williams B, Mancia G, Spiering W, Rosei EA, Azizi M, Burnier M, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. J Hypertens [Internet]. 2018;36:1956–2041. https://pubmed.ncbi.nlm.nih.gov/30234752/. Accessed 26 Jan 2022.

Cited by

See all 18

Metadata

Authors
Sahoo, S. K., Pathni, A. K., Krishna, A., Sharma, B., Cazabon, D., Moran, A. E., & Hering, D.
Affiliations
  • Resolve to Save Lives (US)
  • Columbia University Irving Medical Center (US)
  • Gdańsk Medical University (PL)
Corresponding author
Hering, Dagmara
Venue
Journal of Human Hypertension
Published
2022-10-21
Volume
37
Issue
9
Pages
828-834
ISSN
  • 0950-9240 (ISSN-L)
  • 1476-5527
OpenAlex
W4307090199
Cited by
18
References
17
Citations by year
2026: 4 · 2025: 5 · 2024: 5 · 2023: 3 · 2022: 1
FWCI
2.44
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of Human Hypertension (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by-nc-sa)
  • PubMed (publishedVersion)
Funders
Resolve to Save Lives
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Healthcare Systems and Reforms
Keywords
antihypertensive therapy, drug costs, treatment protocols, amlodipine, telmisartan, chlorthalidone, single-pill combination, generic drug prices, public and private health sectors, hypertension control program, cost-effectiveness, India
MeSH terms
Telmisartan, Chlorthalidone, Humans, Hypertension, India, Private Sector, Amlodipine

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Financial implications of protocol-based hypertension treatment: an insight into medication costs in public and private health sectors in India. https://app.cochat.ai/papers/10.1038/s41371-022-00766-x
The paper
Sahoo, S. K., Pathni, A. K., Krishna, A., Sharma, B., Cazabon, D., Moran, A. E., & Hering, D. (2022). Financial implications of protocol-based hypertension treatment: an insight into medication costs in public and private health sectors in India. Journal of Human Hypertension. https://doi.org/10.1038/s41371-022-00766-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.